Neurotherapeutics company MindMaze Therapeutics has announced it has raised CHF 8 million (€8.7 million) in strategic equity financing. 

The financing has been raised through a definitive agreement with Neuro.io, which will acquire a strategic equity position in the company. 

MindMaze Therapeutics says it will use the funds raised to support the company’s commercial priorities, including scaling its US footprint and advancing deployment of its neurotherapeutics solutions. 

The two companies have also said they will begin discussions on opportunities to combine MindMaze Therapeutics’ clinically validated neurotherapeutics platform with Neuro.io’s healthcare-focused AI and compute capabilities. The companies could look to collaborate to support the development and deployment of AI-enabled interventions targeting neurological disorders. 

“This financing meaningfully strengthens our financial position and supports continued execution of our commercial and strategic priorities as we scale deployment of our neurotherapeutics solutions,” said Zach Henderson, Chief Executive Officer of MindMaze Therapeutics.  

“We are also pleased to initiate partnership discussions with Neuro.io around expanding our AI capabilities.”